Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Surgery Partners (SGRY) over the last 12 years, with Q3 2025 value amounting to $203.4 million.

  • Surgery Partners' Cash & Equivalents fell 829.58% to $203.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $203.4 million, marking a year-over-year decrease of 829.58%. This contributed to the annual value of $269.5 million for FY2024, which is 3757.02% up from last year.
  • Per Surgery Partners' latest filing, its Cash & Equivalents stood at $203.4 million for Q3 2025, which was down 829.58% from $250.1 million recorded in Q2 2025.
  • Over the past 5 years, Surgery Partners' Cash & Equivalents peaked at $541.9 million during Q1 2021, and registered a low of $154.8 million during Q3 2022.
  • Over the past 5 years, Surgery Partners' median Cash & Equivalents value was $236.0 million (recorded in 2023), while the average stood at $273.6 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 17846.87% in 2021, then tumbled by 5314.77% in 2022.
  • Over the past 5 years, Surgery Partners' Cash & Equivalents (Quarter) stood at $389.9 million in 2021, then dropped by 27.44% to $282.9 million in 2022, then plummeted by 30.75% to $195.9 million in 2023, then skyrocketed by 37.57% to $269.5 million in 2024, then dropped by 24.53% to $203.4 million in 2025.
  • Its Cash & Equivalents stands at $203.4 million for Q3 2025, versus $250.1 million for Q2 2025 and $229.3 million for Q1 2025.